QPS Netherlands B.V.
Groningen, 9713 GZ, Netherlands
NCT Number: NCT04798209
A study to examine the safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of ACT-777991 in healthy subjects.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Groningen, 9713 GZ, Netherlands
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
General Inclusion Criteria:
Inclusion criteria
for Part B:
General Exclusion Criteria:
Exclusion criteria
for the absorption,distribution, metabolism and excretion (ADME) evaluation:
Exclusion criteria
for Part B:
ACT-777991 administered as hard capsules for oral use.
ACT-777991 administered as hard capsules for oral use, once daily.
ACT-777991 matching placebo administered as hard capsules for oral use.
Matching placebo administered as hard capsules for oral use, once daily.
Single dose of 14C-ACT-777991 microtracer, administered intravenously.
Single dose of 14C-ACT-777991 microtracer matching placebo, administered intravenously.
Single dose of 14C-ACT-777991 microtracer, oral solution..
Single dose of 14C-ACT-777991 microtracer matching placebo, oral solution.
Time frame: From first dose on Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Samples will be collected at predefined time points from Day 1 to Day X+3 (where Day X = day of last study treatment administration)
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4 after the last dose was administered
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Time frame: Blood samples will be collected at predefined time points from Day 1 to Day 4.
Idorsia Pharmaceuticals Ltd.
Industry
A Single-center, Double-blind, Randomized, Placebo-controlled Phase 1 Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Single- and Multiple-ascending Doses of ACT-777991 in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsNCT06702423
Healthy
London, United Kingdom
View Trial DetailsNCT07223164
Healthy
Irvine, California, United States
View Trial DetailsNCT05595902
Healthy
Kadıköy, Istanbul, Turkey (Türkiye)
View Trial Details